GlassScriptPhysician profile
Steven A Harris
NPI 1912985631
$3,181.82
in general payments reported to CMS, 2019-2025
30 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $152 · 2021: $364 · 2022: $587 · 2023: $685 · 2024: $619 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.45 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $468.25 | 2023-2025 | Myfembree |
| Abbvie INC. | $389.20 | 2019-2025 | |
| Organon LLC | $304.12 | 2021-2024 | Nexplanon |
| Pfizer INC. | $250.45 | 2022-2024 | |
| Astellas Pharma US INC | $226.47 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $223.85 | 2021-2025 | |
| Exeltis, USA INC. | $170.07 | 2019-2023 | Slynd |
| Coopersurgical, INC. | $156.57 | 2020-2025 | Summit Doppler, Endosee |
| Myovant Sciences INC. | $131.25 | 2021-2022 | |
| Shield Therapeutics INC | $129.26 | 2022-2024 | |
| Hologic Sales and Service, LLC | $128.48 | 2019-2023 | Myosure Tissue Removal Device, Acessa Provu System, Coolseal Generator |
| Therapeuticsmd, INC. | $92.47 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.75 | 2025 | |
| Allergan, INC. | $58.38 | 2019-2020 | |
| Daiichi Sankyo INC. | $53.06 | 2023 | Injectafer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $46.95 | 2020-2023 | Balcoltra |
| Amag Pharmaceuticals, INC. | $41.43 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.62 | 2019-2020 | |
| Channel Medsystems, INC. | $35.43 | 2021 | |
| Lupin INC. | $31.49 | 2020-2021 | |
| Scynexis, INC. | $22.39 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.17 | 2022 | |
| Virtus Pharmaceuticals LLC | $21.04 | 2022 | |
| Meditrina | $16.65 | 2025 | |
| Ethicon US, LLC | $16.45 | 2020 | |
| Duchesnay USA Incorporated | $13.82 | 2019 | |
| Aspira Women'S Health INC | $13.81 | 2023 | Ova1 |
| Smith+Nephew, INC. | $11.22 | 2019 | |
| Bolder Surgical LLC | $6.72 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.